Psoriatic Arthritis Treated With Liraglutide Therapy: a QUality of Life and Efficacy Study
Status:
Withdrawn
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
Exploratory, double-blind randomized, placebo-controlled, Phase II study to evaluate the
effect(s) of short-term administration of liraglutide, a GLP-1R (glucagon-like peptide-1
receptor) agonist on joint and skin inflammation in patients with active Psoriatic Arthritis.